Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update
– Company plans to file IND for Ziopharm TCR-T program   in Q1   of next year for its  Library “hotspot” trial   – – Eden BioCell on track for IND filing i n Taiwan   for autologus CAR-T clinical trial this year based on rapid personalized manufacturing ; several patients dosed under compassionate
View HTML
Toggle Summary Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders
Urges Shareholders to Sign and Return Ziopharm’s GREEN Consent Revocation Card Emphasizes that Substantial Board Refr eshment is Already in Process Reiterates Commitment to Implementing Strategy and Delivering Significant Value to S hareholders Questions WaterMill’s Attempt to Seize Outsize d
View HTML
Toggle Summary Ziopharm Oncology to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 5, 2020
BOSTON , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, November 5 , at 4:30 pm EDT to provide a corporate update and discuss financial results for the third quarter ended September 30, 2020
View HTML
Toggle Summary Ziopharm Oncology Announces Receipt of Shareholders’ Intent to Solicit Written Consents
BOSTON , Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a preliminary consent solicitation statement by WaterMill Asset Management Corp. , Mr. Robert W.
View HTML
Toggle Summary Ziopharm Oncology to Participate in Jefferies Cell Therapy Virtual Summit on October 5, 2020
BOSTON , Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the 7 th Annual Jefferies Cell Therapy Virtual Summit on October 5, 2020 at
View HTML
Toggle Summary Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors
– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively  as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva – – Doug Pagán Steps Down from Board of Directors – BOSTON , Sept. 22, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc.
View HTML
Toggle Summary Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board
BOSTON , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB). The SAB , under the leadership of Carl June , M.D.
View HTML
Toggle Summary Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG
BOSTON , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational
View HTML
Toggle Summary Ziopharm Oncology to Participate in Upcoming Conferences
BOSTON , Sept. 10, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper , M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in two upcoming conferences: H.C. Wainwright 22nd Annual Global Investment Conference   Date:  
View HTML
Toggle Summary Ziopharm Oncology Reports Second Quarter 2020 Financial Results and Provides Corporate Update
– Enrollment completed in Controlled IL-12 phase 2 clinical trial with Regeneron’s Libtayo ® – – First patient with DIPG dosed in phase 1/2 pediatric brain tumor trial of Contolled IL-12 – – Work restrictions at the NCI and MD Anderson easing; MD Anderson initiated phase 1 CD19-specific CAR-T
View HTML